[Drug delivery to target the posterior segment of the eye].
Retinal diseases are nowadays the most common causes of vision threatening in developed countries. Therapeutic advances in this field are hindered by the difficulty to deliver drugs to the posterior segment of the eye. Due to anatomical barriers, the ocular biodisponibility of systemically administered drugs remains poor, and topical instillation is not adequate to achieve therapeutic concentrations of drugs in the back of the eye. Ocular drug delivery has thus become one of the main challenges of modern ophthalmology. A multidisciplinary research is being conducted worldwide including pharmacology, biomaterials, ophthalmology, pharmaceutics, and biology. New promising fields have been developed such as implantable or injectable slow release intravitreal devices and degradable polymers, dispersed polymeric systems for intraocular drug delivery, and transscleral delivery devices such as iontophoresis, osmotic pumps or intra-scleraly implantable materials. The first clinical applications emerging from this research are now taking place, opening new avenues for the treatment of retinal diseases.
Inserm U.598, 15, rue de l'Ecole de Médecine, 75006 Paris, France. Fondation ophtalmologique A. de Rothschild, 25, rue Manin, 75019 Paris, France.
Francine
F
Behar-Cohen
D035843:Biomedical Research; D016503:Drug Delivery Systems; D006801:Humans; D015552:Injections, Intralesional; D012164:Retinal Diseases / Q000188:drug therapy*